{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:26:17Z","timestamp":1772774777387,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Cilag S.A.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5974-9","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T12:02:33Z","timestamp":1565006553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-1331","authenticated-orcid":false,"given":"Javier","family":"Puente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aranzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Sala-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"M\u00e9ndez-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Miguel","family":"Cuevas Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobo Rodrigo","family":"Mu\u00f1oz del Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Useros Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela","family":"Garc\u00eda Garc\u00eda-Porrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"5974_CR1","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293\u20137.","journal-title":"Cancer Res"},{"key":"5974_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387:70\u201382.","journal-title":"Lancet."},{"key":"5974_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"5974_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.juro.2014.10.104","volume":"193","author":"MS Cookson","year":"2015","unstructured":"Cookson MS, Lowrance WT, Murad MH, Kibel AS. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015;193:491\u20139.","journal-title":"J Urol"},{"key":"5974_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4405","volume":"355","author":"CR Ritch","year":"2016","unstructured":"Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016;355:i4405.","journal-title":"BMJ."},{"key":"5974_CR6","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.2217\/fon.15.217","volume":"11","author":"S Bracarda","year":"2015","unstructured":"Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, et al. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation. Future Oncol. 2015;11:3083\u201390.","journal-title":"Future Oncol"},{"key":"5974_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.critrevonc.2015.05.019","volume":"96","author":"MA Climent","year":"2015","unstructured":"Climent MA, Leon-Mateos L, Del Alba AG, Perez-Valderrama B, Mendez-Vidal MJ, Mellado B, et al. Updated recommendations from the Spanish oncology genitourinary group for the treatment of patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015;96:308\u201318.","journal-title":"Crit Rev Oncol Hematol"},{"key":"5974_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.urology.2016.12.033","volume":"104","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, et al. The role of therapeutic layering in optimizing treatment for patients with castration-resistant prostate cancer (prostate Cancer radiographic assessments for detection of advanced recurrence II). Urology. 2017;104:150\u20139.","journal-title":"Urology."},{"key":"5974_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12094-017-1783-2","volume":"20","author":"J Cassinello","year":"2018","unstructured":"Cassinello J, Arranz JA, Piulats JM, Sanchez A, Perez-Valderrama B, Mellado B, et al. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol. 2018;20:57\u201368.","journal-title":"Clin Transl Oncol"},{"key":"5974_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00345-015-1687-0","volume":"34","author":"S Lebdai","year":"2016","unstructured":"Lebdai S, Basset V, Branchereau J, de la Taille A, Flamand V, Lebret T, et al. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? World J Urol. 2016;34:617\u201324.","journal-title":"World J Urol"},{"key":"5974_CR11","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1016\/j.clgc.2016.12.015","volume":"15","author":"H Miyake","year":"2016","unstructured":"Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, et al. Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2016;15:e591\u20137.","journal-title":"Clin Genitourin Cancer"},{"key":"5974_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/pros.23246","volume":"77","author":"BL Maughan","year":"2017","unstructured":"Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate. 2017;77:33\u201340.","journal-title":"Prostate."},{"key":"5974_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12032-017-1014-2","volume":"34","author":"WK Oh","year":"2017","unstructured":"Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, et al. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Med Oncol. 2017;34:160.","journal-title":"Med Oncol"},{"key":"5974_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"5974_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3109\/21681805.2016.1172254","volume":"50","author":"J Svensson","year":"2016","unstructured":"Svensson J, Andersson E, Persson U, Edekling T, Ovanfors A, Ahlgren G. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden. Scand J Urol. 2016;50:286\u201391.","journal-title":"Scand J Urol"},{"key":"5974_CR16","doi-asserted-by":"publisher","first-page":"254.e7","DOI":"10.1016\/j.urolonc.2015.12.017","volume":"34","author":"C van Praet","year":"2016","unstructured":"van Praet C, Rottey S, van Hende F, Pelgrims G, Demey W, van Aelst F, et al. Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program. Urol Oncol. 2016;34:254.e7\u201313.","journal-title":"Urol Oncol"},{"key":"5974_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet."},{"key":"5974_CR18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.euf.2016.09.008","volume":"4","author":"HM Westgeest","year":"2016","unstructured":"Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen J, et al. Differences in trial and real-world populations in the dutch castration-resistant prostate cancer registry. Eur Urol Focus. 2016;4:694\u2013701.","journal-title":"Eur Urol Focus"},{"key":"5974_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195790","volume":"13","author":"JP Fryzek","year":"2018","unstructured":"Fryzek JP, Reichert H, Summers N, Townes L, Deuson R, Alexander DD, et al. Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PLoS One. 2018;13:e0195790.","journal-title":"PLoS One"},{"key":"5974_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"5974_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"5974_CR22","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","volume":"71","author":"JS de Bono","year":"2017","unstructured":"de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PF, Small EJ, et al. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;71:656\u201364.","journal-title":"Eur Urol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5974-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5974-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5974-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T23:11:08Z","timestamp":1596496268000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5974-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5974"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5974-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by the Ethics Committee of the Hospital Cl\u00ednico San Carlos (Madrid, Spain). All patients provided written informed consent before being included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JP has received honoraria as consultant on advisory boards from Pfizer, Astellas, Janssen, MSD, Bayer, Roche, BMS, Boehringer, Astra Zeneca, Ipsen, Novartis, Eusa Pharma, Eisai and Sanofi; and as speaker from Kyowa, Pierre-Fabre, Celgene, Lilly and Merck; and has received travel grants from Pfizer, Roche and BMS. AGA has received honoraria as consultant on advisory boards from Astellas, Janssen, Bayer, Sanofi, Roche, BMS, MSD, Ipsen, Novartis, Pfizer, Eusa Pharma, Eisai and as speaker from Astellas, Bayer, Roche, Ipsen, Janssen, Pfizer, Novartis, Sanofi; she has received travel grants from Pfizer, Roche, BMS, Astellas, Janssen, Sanofi, MSD, and research grants from Astellas. NSG has received honoraria as consultant on advisory boards from Pfizer, Bayer and travel grants from Pfizer. MJMV has received honoraria and\/or travel support from Janssen-Cilag, Bayer healthcare, Sanofi Aventis, Astellas Medivation, Roche, BMS, Novartis and Pfizer. AP has received advisory and consulting honorarium from Astellas, Janssen, Bayer, Clovis, Sanofi, Pfizer, Novartis, BMS, Roche, MSD, Pierre-Fabre, Ipsen; he has received travel grants from Pfizer, Janssen, Roche. AR has received honoraria as consultant on advisory boards from Janssen, MSD, Bayer, Roche, Novartis and Sanofi. JMCS has no conflict of interest related with this manuscript. JRMT, EUR, and AGGP are full-time employees for Medical Affairs Department Janssen Spain. SV has received honoraria as consultant on advisory boards from Pfizer, Astellas, Janssen, MSD, Bayer, Roche, BMS, Boehringer, AstraZeneca, Ipsen, Novartis, Eusa Pharma, Eisa and Sanofi, and as speaker from Lilly, Astellas, Bayer, Roche, Boehringer, Ipsen, Novartis, astra Zeneca and Sanofi; he has received travel grants from Pfizer, Roche and Astra Zeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"766"}}